Rocket Lab’s selloff is the market telling investors something important: the Iridium deal changed the stock. An $8 billion cash-and-stock acquisition backed by a $3.6 billion bridge loan shifts RKLB away from a simple launch-and-Neutron growth narrative and toward a much harder question of integration, leverage, and execution. That matters because this was already an expensive stock before the deal, trading at 79.29 times sales while still posting a -26.9% net margin. The debate is no longer just how fast Rocket Lab can grow; it is whether a bigger, more complex space platform deserves the same multiple.
The size of the transaction is the first reason the market is re-rating the story. Rocket Lab generated $601.80 million of revenue, while Iridium produced $871 million in 2025, which means this is not a tuck-in acquisition but a business combination that is larger than Rocket Lab’s current operating base in key respects. Management is explicitly pitching a vertically integrated space platform with communications, spectrum, and services layered on top of launch. That may be strategically compelling, but it also means investors now have to underwrite a different company than the one they owned a week ago.
The financing angle is the second reason the stock is acting differently. A $3.6 billion 364-day senior secured bridge loan brings capital structure risk to the center of the story, and that is a major change for a company whose appeal was largely tied to growth and optionality. RKLB’s TickerSpark Score captures the split well: Growth is a strong 70 and Financial Health is 84, but Valuation is just 20 and Profitability is 35. That combination works better when the market is willing to pay up for a focused growth story; it gets tougher when the narrative shifts toward debt, refinancing, and integration discipline.
The valuation was already stretched enough that any change in the story could force a reset. Rocket Lab is growing fast, with revenue up 38.0% year over year, but it is also losing money, with operating margin at -33.2% and net income at -$198.21 million. Against peers, the premium is obvious: HEICO trades at 10.36 times sales with a 16.1% net margin, while Verisk sits at 8.10 times sales with a 29.3% net margin. RKLB at 79.29 times sales only made sense if investors were paying for a cleaner, more singular growth arc. Once that arc becomes an M&A integration story, the multiple has to work a lot harder.
There is a real bull case here, and it is not hard to see why sentiment has stayed strong. News sentiment over the last week is still strongly positive at 0.7818, analysts still lean constructive with 15 buys against 4 holds and 1 sell, and the strategic logic is easy to pitch: Iridium adds scale, cash generation, spectrum exposure, and a broader platform that could make Rocket Lab more than a launch company. If the market ultimately decides the combined business deserves a higher-quality multiple, today’s weakness will look temporary.
That said, the tape is saying investors are not ready to grant that benefit of the doubt yet. RKLB is below both its 20-day moving average of 100.12 and 50-day moving average of 107.1, with OBV trending toward distribution, even though the stock remains above its 200-day average of 76.32. That is exactly what a narrative transition looks like: long-term belief intact, short-term confidence shaken. Add in two recent insider sales totaling $14.45 million and the burden of proof clearly sits with management now, not with skeptical shareholders.
That leaves RKLB in a very different bucket than the one many retail investors think they still own. We would treat this as a platform-transition stock, not a pure launch-growth stock, until management proves the Iridium deal can be financed cleanly and integrated without breaking the operating story. The next real checkpoint is the August 6 earnings report, where the market will want specifics on deal rationale, financing path, and how Neutron and launch cadence stay on track while a much bigger transaction moves toward an expected 2027 close.
We would not chase the old thesis here as if nothing changed. The trigger that would make us more constructive is evidence that Rocket Lab can keep its 38.0% revenue growth profile while giving investors a credible path through the financing overhang and toward better profitability. Until then, the selloff looks less like a bargain and more like the market correctly demanding a new valuation framework for a newly complicated company.
